[Effect of Autologous Hematopoietic Stem Cell Transplantation on Recurrent Refractory B Cell NHL and Its Factors Influencing Prognosis].

OBJECTIVE: To analyze the effect of autologous hematopoietic stem cell transplantation in the treatment of patients with recurrent refractory B cell non-Hodgkin's lymphoma (NHL) and the related factors affecting the prognosis.

METHODS: The clinical data of 47 cases of recurrent refractory B cell NHL treated in our hospital were retrospectively analyzed. Survival curves were drawn by Kaplan-Meier, and survival analyses were performed. Univariate and multivariate analyses were used to analyze the prognostic factors.

RESULTS: The complete remission rate was 51.06% before autologous hematopoietic stem cell transplantation, but it increased to 65.96% after transplantation. The median survival time was 21 months, the 3 years progression-free survival rate was 40.43%, and the 3 years overall survival rate was 48.94%. The results of unvariate analysis showed that no using the rituximab in the first treatment and incomplete remission shown by PET/CT before transplantation all were the risk factors (P<0.05) affecting the prognosis. By multifactor analysis, it was found that the incomplete remission shown by PET/CT before transplantation was a risk factor for the prognosis(P<0.05).

CONCLUSION: The application of autologous hematopoietic stem cell transplantation for patients with relapsed and refractory B cell NHL can improve the clinical efficacy, and the incomplete remission shown by PET/CT before transplantation is more adverse to the patients' prognosis.